This page is updated frequently with new Nephropathy-related patent applications.
| Therapy for complications of diabetes|
A method for enhancing glycemic control and/or insulin sensitivity to a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin a (eta) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective eta receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective eta receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension.
Abbvie Deutschland Gmbh & Co. Kg
|Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses|
The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, alzheimer's disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, syndrome x, thrombotic disorder. Compounds and methods of the invention can also be used to modulate c reactive protein or enhance bile production in a patient.
Esperion Therapeutics, Inc.
|In vitro diagnostic and prognosis of major adverse events in patients undergoing coronary angiography|
Method of diagnosis and prognosis of contrast media induced nephropathy (cin) comprising the steps of i) taking a urine sample from a patient exposed to the application of contrast media, notably patients subjected to coronary angiography; ii) assessing the level of vitamin d binding protein (vdbp) in the urine sample obtained in step (i); iii) relating the urinary vitamin d binding protein level determined in step (ii) to a pre-selected threshold level, wherein a urinary vitamin d binding level higher than said pre-selected threshold level indicates that the patient is at risk of renal failure and in need of a dialysis treatment.. .
|Substituted pyridazines as prostacyclin receptor modulators|
Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.
|Pegylated tissue kallikrein, and preparation method therefor and uses thereof|
The present invention relates to polyethylene glycol (peg) modified protein drugs, and a pegylated tissue kallikrein, a preparation method and use thereof are disclosed. The tissue kallikrein has a sequence as shown in seq id no.
Gensun Institute Of Biomedicine Co.,ltd.
|Acetylcysteine composition and uses thereof|
This invention relates to novel acetylcysteine compositions in solution, comprising acetylcysteine and which are substantially free of metal chelating agents, such as edta. Further, this invention relates to methods of making and using the acetylcysteine compositions.
Cumberland Pharmaceuticals, Inc.
|Anti-human il-21 antibodies|
Monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
|Method of treating nephropathy|
The present disclosure provides a method of treating diabetic nephropathy in a subject suffering from diabetic nephropathy, the method comprising administering to the subject a compound that inhibits vegf-b signalling.. .
B-creative Sweden Ab
|Treatment of nephropathy|
The present invention relates to the treatment of kidney diseases, both acute and chronic. The invention in particular relates to the use of neuregulins for preventing, treating or delaying kidney diseases..
The invention relates to a biomarker useful for the diagnosis of kidney disease and for determining patients whose disease severity level is likely to progress. The invention provides methods and products for determining the propensity for kidney disease progression..
Epsom And St Helier University Hospitals Nhs Trust
Detecting podocyte injury in diabetic nephropathy and glomerulonephritis
This document provides methods and materials involved in determining whether or not a mammal with diabetic nephropathy or glomerulonephritis is undergoing podocyte injury. For example, methods and materials related to the use of urinary microvesicles to determine whether or not a mammal with diabetic nephropathy or glomerulonephritis is undergoing podocyte injury are provided..
Mayo Foundation For Medical Education And Research
Methods for treating disorders that involve immunoglobulin a
Provided herein are fdc-sp polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering iga concentration in a subject, treating a subject having signs of a disorder that includes excessive iga production, identifying a compound that decreases the concentration of iga in an animal, and identifying a compound that treats a condition associated with increased levels of iga.
University Of Manitoba
Pharmaceutical compositions for preventing or treating diabetic nephropathy comprising the activity inhibitor of tenc1
Provided is a pharmaceutical composition for preventing or treating diabetic nephropathy, comprising a tensin like c1 domain containing phosphatase (tenc1) inhibitor as an active ingredient. A new target for treating diabetic nephropathy is presented by confirming that tenc1 expression is increased in kidney tissue of diabetes or a podocyte cell line to which a high blood glucose environment is given and experimentally proving that nephrin phosphorylation inhibited by the ptpase activity of tenc1 affects the permeability and mtorc1 signaling of the podocytes resulting in inducing podocyte hypertrophy.
Postech Academy-industry Foundation
Methods for treatment of nephrotic syndrome and related conditions
The present disclosure provides a polypeptide and method for treating and/or preventing nephrotic syndrome, such as but not limited to those associated with minimal change disease and membranous nephropathy, and conditions related to nephrotic syndrome, such as but not limited to, proteinuria and edema, as well as diabetic nephropathy, diabetes mellitus, lupus nephritis or primary glomerular disease. The present disclosure further provides methods for reducing proteinuria and other disease states as discussed herein.
The Uab Research Foundation
Nitrogenous heterocyclic derivatives and their application in drugs
The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, ipf, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis..
Sunshine Lake Pharma Co., Ltd.
Compounds of chemically modified oligonucleotides and methods of use thereof
The present disclosure relates to isolated compounds including a nucleic acid sequence capable of hybridizing to an rna sequence 10 to 270 nucleobases downstream of the transcription start site of a mammalian microrna-379 transcript; method of treating diabetic nephropathy in a subject with the compounds; and method of inhibiting expression of a mammalian microrna-379 megacluster with the compounds.. .
City Of Hope
Agents, methods and kits for treating and detecting diabetic nephropathy and proliferative diseases and methods for inhibiting expression of type iv collagen
A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of stat3, phosphorylated stat3, smad1, phosphorylated smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor.
Hubit Genomix Inc.
Novel peptidomimetics with antiangiogenic activity
We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (armd), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.. .
Uniwersytet Warszawski (heir Of The Deseased Inventor)
Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
The present invention relates to compounds of the formula (i), wherein r1, r2, r3, r4 and x have the meanings indicated in the claims. The compounds of formula i are valuable pharmacologically active compounds.
Method of inhibiting the glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids
Methods for reducing the glycation of nutrient and endogenous proteins and methods for reducing the peroxidation of nutrient and endogenous lipids are provided herein. Several inhibitors and conditions of inhibiting glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids are also provided herein.
Apoptosis signal-regulating kinase inhibitors
The present application relates to compounds having the inhibitory activity to apoptosis signal-regulating kinase (ask1), thus are thus useful in treating ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases.. .
Gilead Sciences, Inc.
Compositions and methods for treating diabetic nephropathy
This invention generally relates to methods and biomarkers for assessing a subject's susceptibility to developing diabetic nephropathy, or for assessing the progression of diabetic nephropathy in a subject. The invention also relates to methods of treating diabetic nephropathy, and methods for identifying a candidate agent for treating diabetic nephropathy..
Rush University Medical Center
Processes for preparing ask1 inhibitors
Which exhibits apoptosis signal-regulating kinase (“ask1”) inhibitory activity and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis. The disclosure also provides compounds that are synthetic intermediates..
Apoptosis signal-regulating kinase inhibitor
The compound has apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.. .
Effect of garcinol in delaying the progression of diabetic nephropathy
The present invention relates to the use of garcinol as a nephroprotective agent. The present invention also relates to the use of garcinol as a therapeutic agent in renal disorders, in particular diabetic nephropathy, and to medicinal preparations containing garcinol.
Delhi Institute Of Pharmaceutical Sciences And Research
Agent for preventing or ameliorating renal dysfunction
An object of the present invention is to provide an agent for preventing or ameliorating renal dysfunction, excellent in the inhibitory action on the advance of renal dysfunction, the suppressive action on renal fibrosis, the suppressive action on the development of renal failure, and the suppressive action on nephritis. The administration of an agent for preventing or ameliorating renal dysfunction, containing lubiprostone or its pharmacologically acceptable salt as an active ingredient by a method, such as oral administration, can inhibit the advance of renal dysfunction, suppress renal fibrosis, suppress the development of renal failure, and suppress nephritis, and thus can prevent or ameliorate nephritides, such as acute glomerulonephritis, minimal change nephritis, chronic glomerulonephritis, renal sclerosis, membrane proliferative nephritis, mesangial proliferative glomerulonephritis, membrane proliferative glomerulonephritis, crescentic nephritis, rapidly progressive glomerulonephritis, membranous glomerulonephritis, tubulointerstitial nephritis, acute pyelonephritis, chronic pyelonephritis, endocapillary proliferative nephritis, and lupus nephritis; renal failures, such as acute renal failure and chronic renal failure; and renal dysfunctions, such as amyloid kidney, membranous nephropathy, focal glomerulosclerosis, iga nephropathy, acute tubular necrosis, nephrotic syndrome, diabetic nephropathy, gouty kidney, renal edema, renal tumors, renal ischemic disorders, and renal ischemia-reperfusion injury..
Detection of risk of pre-eclampsia
A method for the early prediction of risk of hypertensive disorders in pregnant women, including for example eclampsia, mild pre-eclampsia, chronic hypertension, eph gestosis, gestational hypertension, superimposed pre-eclampsia, hellp syndrome, or nephropathy.. .
University College Cork, National University Of Ireland, Cork
Urine exosome mrnas and methods of using same to detect diabetic nephropathy
Embodiments of the invention relate generally to methods of identifying subjects likely to develop diabetes-associated damage to the nephron, or subjects in the early stages of diabetic nephropathy. In particular, several embodiments relate to quantification of diabetic nephropathy-associated markers by isolating rna isolated from vesicles from patient urine samples.
The Regents Of The University Of California
Congestive Heart Failure
Follow us on Twitter
This listing is a sample listing of patent applications related to Nephropathy for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Nephropathy with additional patents listed. Browse our RSS directory or Search for other possible listings.